Among the rhodanine derivatives, 5-[4-(4-fluorophenoxy) phenyl]methylene-3-{4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl}-2-thioxo-4-thiazolidinone dihydrochloride (KSK05104; Figure 1A) showed excellent selectivity IKKβ over other kinases and had a high potential as drug candidate in the development of therapeutics for the treatment of NF-κB associated immune disease such as cancer. The gene discussed is NFKB1; the disease is cancer.